血液透析是肾衰竭患者维持生命的关键治疗手段，透析用水的质量影响治疗安全性和效果。为保障透析用水符合临床需求，我国于2022年7月1日发布行业标准《血液透析和相关治疗用液体的制备和质量管理 第1部分：血液透析和相关治疗用水处理设备》(YY/T 0793.1-2022)，该标准于2024年7月1日正式实施。YY/T 0793.1-2022在国际标准ISO 23500-2:2019 的基础上，结合我国临床、行业、监管及标准体系进行了修订。本文通过对比旧版YY 0793.1-2010/YY 0793.2-2011和YY/T 0793.1-2022 主要技术性差异，对新版标准的关键条款进行解读，旨在为行业理解和贯彻该标准提供参考，推动行业高质量发展，为血液透析用水的安全提供更为可靠的技术支撑。

Hemodialysis is a critical life-sustaining therapy for patients with end-stage renal failure. The quality of dialysis water affects treatment safety and efficacy. To ensure the clinical requirements of dialysis water, YY/T 0793.1-2022 was issued on July 1, 2022, and has been implemented since July 1 2024. YY/T 0793.1-2022 is revised based on the international standard ISO 23500-2:2019, incorporating our own clinical practice, industry conditions, regulatory requirements, and national standard system. This paper compares the major technical differences between the older versions YY 0793.1‑2010/YY 0793.2‑2011 and the new version YY/T 0793.1-2022, and interprets the key clauses in the new version, aiming to provide the industry with understanding and implementing the standard, the guidance on high-quality development and reliable technical support for safety of hemodialysis water.